pLL-EF1a-RFP-T2A-Blast Lenti-Labeler™ Lentivector Plasmid & Pre-packaged Virus
- Proven—leverages SBI’s third generation lentivector technology for optimal virus titers
- Validated—sequence-verified from LTR to LTR and expression-verified in HT-1080 cells
- Flexible—available in a range of fluorescent markers, selection markers, and promoters (Table 1)
Products
Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
---|---|---|---|---|---|---|---|---|
LL215PA-1 | pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ plasmid) | 10 µg | $635 |
|
||||
LL215VA-1 | pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ virus) | >2x10^6 IFUs | $635 |
|
Overview
Overview
Reliable cell labeling, delivered
SBI’s family of Lenti-Labeler™ constructs facilitate a wide range of studies—including cell tracking, high-throughput assays, and more—by enabling efficient and reliable labeling of your cells. The pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ construct expresses RFP from the EF1α promoter, which delivers moderate expression in most cell types (including primary and stem cells), and co-expresses the blasticidin resistance gene for selection in vitro prior to in vivo use. Available as either fully propagatable, sequence-verified plasmid DNA (Cat.# LL215PA-1) or ready-to-transduce pre-packaged lentivirus (Cat.# LL215VA-1), SBI’s pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ is designed for reliability, so you can get to valuable insights faster.
- Proven—leverages SBI’s third generation lentivector technology for optimal virus titers
- Validated—sequence-verified from LTR to LTR and expression-verified in HT-1080 cells
- Flexible—available in a range of fluorescent markers, selection markers, and promoters (Table 1)
While the pLL-EF1α-RFP-T2A-Blast Lenti-Labeler construct is compatible with most second and third generation packaging plasmid mixes, SBI recommends the use of pPACKH1 (Cat #LV500A-1) and TransDux MAX Transduction Reagent (Cat #LV860A-1) to achieve optimal virus titers and infection of target cells.
Find the right Lenti-Labeler construct for your studies
SBI offers Lenti-Labeler constructs with a range of selection markers, reporter genes, and two different promoters.
Table 1. Available Lenti-Labeler Constructs
Cat. # | Construct | Promoter | Reporter | Selection |
---|---|---|---|---|
LL100PA-1/LL100VA-1 | pLL-CMV-GFP-T2A-Puro | CMV | GFP | Puromycin |
LL105PA-1/LL105VA-1 | pLL-CMV-GFP-T2A-Blast | CMV | GFP | Blasticidin |
LL110PA-1/LL110VA-1 | pLL-CMV-RFP-T2A-Puro | CMV | RFP | Puromycin |
LL115PA-1/LL115VA-1 | pLL-CMV-RFP-T2A-Blast | CMV | RFP | Blasticidin |
LL120PA-1/LL120VA-1 | pLL-CMV-BFP-T2A-Puro | CMV | BFP | Puromycin |
LL125PA-1/LL125VA-1 | pLL-CMV-BFP-T2A-Blast | CMV | BFP | Blasticidin |
LL150PA-1/LL150VA-1 | pLL-CMV-Luciferase-T2A-Puro | CMV | Luciferase | Puromycin |
LL200PA-1/LL200VA-1 | pLL-EF1α-GFP-T2A-Puro | EF1α | GFP | Puromycin |
LL205PA-1/LL205VA-1 | pLL-EF1α-GFP-T2A-Blast | EF1α | GFP | Blasticidin |
LL210PA-1/LL210VA-1 | pLL-EF1α-RFP-T2A-Puro | EF1α | RFP | Puromycin |
LL215PA-1/LL215VA-1 | pLL-EF1α-RFP-T2A-Blast | EF1α | RFP | Blasticidin |
LL220PA-1/LL220VA-1 | pLL-EF1α-BFP-T2A-Puro | EF1α | BFP | Puromycin |
LL225PA-1/LL225VA-1 | pLL-EF1α-BFP-T2A-Blast | EF1α | BFP | Blasticidin |
LL250PA-1/LL250VA-1 | pLL-EF1α-Luciferase-T2A-Puro | EF1α | Luciferase | Puromycin |
LL300PA-1/LL300VA-1 | pLL-CMV-rFLuc-T2A-GFP | CMV | Luciferase & GFP | N/A |
LL310PA-1/LL310VA-1 | pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro | CMV | Luciferase & GFP | Puromycin |
LL320PA-1/LL320VA-1 | pLL-CMV-rFLuc-T2A-mRFP-mPGK-Puro | CMV | Luciferase & RFP | Puromycin |
LL410PA-1/LL410VA-1 | pLL-EF1a-rFLuc-T2A-GFP-mPGK-Puro | EF1α | Luciferase & GFP | Puromycin |
LL420PA-1/LL420VA-1 | pLL-EF1a-rFLuc-T2A-mRFP-mPGK-Puro | EF1α | Luciferase & RFP | Puromycin |
References
How It Works
Supporting Data
FAQs
Related Products
Resources
Citations
-
Abe, Y, et al. (2024) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Communications biology. 2024; 7(1):593. PM ID: 38760429
-
Reavis, HD, et al. (2024) Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. JCI insight. 2024;. PM ID: 38271085
-
Chan, TS, et al. (2024) ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells. Molecular oncology. 2024;. PM ID: 38279565
-
Kang, J, et al. (2024) Depletion of SAM leading to loss of heterochromatin drives muscle stem cell ageing. Nature metabolism. 2024; 6(1):153-168. PM ID: 38243132
-
Wan, Q, et al. (2024) Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. Nature communications. 2024; 15(1):1442. PM ID: 38365882
-
Vilpreux, C, et al. (2024) Sperm motility in mice with Oligo-astheno-teratozoospermia restored by in vivo injection and electroporation of naked mRNA. eLife. 2024;. Link: eLife
-
Yu, BY, et al. (2024) Dimethyl α-Ketoglutarate Promotes the Synthesis of Collagen and Inhibits Metalloproteinases in HaCaT Cells. Biomolecules & therapeutics. 2024; 32(2):240-248. PM ID: 38296652
-
McCorkle, JR, et al. (2024) Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers. 2024; 16(7). PM ID: 38610999
-
Dufner, A, et al. (2024) Ubiquitin-specific protease 8 controls B cell proteostasis and cell survival in multiple myeloma. bioRxiv. 2024;. Link: bioRxiv
-
Uddin, M, et al. (2024) Advancement of Radiolabeled Exosomes in Brain Disorders. Exosomes Based Drug Delivery Strategies for Brain Disorders. 2024;:325-392. Link: Exosomes Based Drug Delivery Strategies for Brain Disorders
-
Lin, RZ, et al. (2024) Mitochondrial transfer mediates endothelial cell engraftment through mitophagy. Nature. 2024; 629(8012):660-668. PM ID: 38693258
-
Abdoul-Azize, S, et al. (2024) Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling. Nature communications. 2024; 15(1):4557. PM ID: 38811530
-
Tanaka, N, et al. (2023) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Research Square. 2023;. Link: Research Square
-
Celik, A, et al. (2023) Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023; 161:114524. PM ID: 36948134
-
Brightman, SE, et al. (2023) Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors. Nature immunology. 2023; 24(8):1345-1357. PM ID: 37400675
-
Jeon, HM, et al. (2023) Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer cell. 2023;. PM ID: 37451272
-
Yamada-Hunter, S, et al. (2023) Engineered CD47 protects T cells for enhanced antitumor immunity. bioRxiv. 2023;. Link: bioRxiv
-
Pearson, S, et al. (2023) Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients. PloS one. 2023; 18(5):e0286412. PM ID: 37253035
-
Campelo, SN, et al. (2023) High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas. Frontiers in oncology. 2023; 13:1171278. PM ID: 37213298
-
Sugita, M, et al. (2023) Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell death & disease. 2023; 14(5):305. PM ID: 37142568
- See More
Products
Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
---|---|---|---|---|---|---|---|---|
LL215PA-1 | pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ plasmid) | 10 µg | $635 |
|
||||
LL215VA-1 | pLL-EF1a-RFP-T2A-Blast (Lenti-Labeler™ virus) | >2x10^6 IFUs | $635 |
|
Overview
Overview
Reliable cell labeling, delivered
SBI’s family of Lenti-Labeler™ constructs facilitate a wide range of studies—including cell tracking, high-throughput assays, and more—by enabling efficient and reliable labeling of your cells. The pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ construct expresses RFP from the EF1α promoter, which delivers moderate expression in most cell types (including primary and stem cells), and co-expresses the blasticidin resistance gene for selection in vitro prior to in vivo use. Available as either fully propagatable, sequence-verified plasmid DNA (Cat.# LL215PA-1) or ready-to-transduce pre-packaged lentivirus (Cat.# LL215VA-1), SBI’s pLL-EF1α-RFP-T2A-Blast Lenti-Labeler™ is designed for reliability, so you can get to valuable insights faster.
- Proven—leverages SBI’s third generation lentivector technology for optimal virus titers
- Validated—sequence-verified from LTR to LTR and expression-verified in HT-1080 cells
- Flexible—available in a range of fluorescent markers, selection markers, and promoters (Table 1)
While the pLL-EF1α-RFP-T2A-Blast Lenti-Labeler construct is compatible with most second and third generation packaging plasmid mixes, SBI recommends the use of pPACKH1 (Cat #LV500A-1) and TransDux MAX Transduction Reagent (Cat #LV860A-1) to achieve optimal virus titers and infection of target cells.
Find the right Lenti-Labeler construct for your studies
SBI offers Lenti-Labeler constructs with a range of selection markers, reporter genes, and two different promoters.
Table 1. Available Lenti-Labeler Constructs
Cat. # | Construct | Promoter | Reporter | Selection |
---|---|---|---|---|
LL100PA-1/LL100VA-1 | pLL-CMV-GFP-T2A-Puro | CMV | GFP | Puromycin |
LL105PA-1/LL105VA-1 | pLL-CMV-GFP-T2A-Blast | CMV | GFP | Blasticidin |
LL110PA-1/LL110VA-1 | pLL-CMV-RFP-T2A-Puro | CMV | RFP | Puromycin |
LL115PA-1/LL115VA-1 | pLL-CMV-RFP-T2A-Blast | CMV | RFP | Blasticidin |
LL120PA-1/LL120VA-1 | pLL-CMV-BFP-T2A-Puro | CMV | BFP | Puromycin |
LL125PA-1/LL125VA-1 | pLL-CMV-BFP-T2A-Blast | CMV | BFP | Blasticidin |
LL150PA-1/LL150VA-1 | pLL-CMV-Luciferase-T2A-Puro | CMV | Luciferase | Puromycin |
LL200PA-1/LL200VA-1 | pLL-EF1α-GFP-T2A-Puro | EF1α | GFP | Puromycin |
LL205PA-1/LL205VA-1 | pLL-EF1α-GFP-T2A-Blast | EF1α | GFP | Blasticidin |
LL210PA-1/LL210VA-1 | pLL-EF1α-RFP-T2A-Puro | EF1α | RFP | Puromycin |
LL215PA-1/LL215VA-1 | pLL-EF1α-RFP-T2A-Blast | EF1α | RFP | Blasticidin |
LL220PA-1/LL220VA-1 | pLL-EF1α-BFP-T2A-Puro | EF1α | BFP | Puromycin |
LL225PA-1/LL225VA-1 | pLL-EF1α-BFP-T2A-Blast | EF1α | BFP | Blasticidin |
LL250PA-1/LL250VA-1 | pLL-EF1α-Luciferase-T2A-Puro | EF1α | Luciferase | Puromycin |
LL300PA-1/LL300VA-1 | pLL-CMV-rFLuc-T2A-GFP | CMV | Luciferase & GFP | N/A |
LL310PA-1/LL310VA-1 | pLL-CMV-rFLuc-T2A-GFP-mPGK-Puro | CMV | Luciferase & GFP | Puromycin |
LL320PA-1/LL320VA-1 | pLL-CMV-rFLuc-T2A-mRFP-mPGK-Puro | CMV | Luciferase & RFP | Puromycin |
LL410PA-1/LL410VA-1 | pLL-EF1a-rFLuc-T2A-GFP-mPGK-Puro | EF1α | Luciferase & GFP | Puromycin |
LL420PA-1/LL420VA-1 | pLL-EF1a-rFLuc-T2A-mRFP-mPGK-Puro | EF1α | Luciferase & RFP | Puromycin |
References
How It Works
FAQs
Citations
-
Abe, Y, et al. (2024) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Communications biology. 2024; 7(1):593. PM ID: 38760429
-
Reavis, HD, et al. (2024) Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells. JCI insight. 2024;. PM ID: 38271085
-
Chan, TS, et al. (2024) ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells. Molecular oncology. 2024;. PM ID: 38279565
-
Kang, J, et al. (2024) Depletion of SAM leading to loss of heterochromatin drives muscle stem cell ageing. Nature metabolism. 2024; 6(1):153-168. PM ID: 38243132
-
Wan, Q, et al. (2024) Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. Nature communications. 2024; 15(1):1442. PM ID: 38365882
-
Vilpreux, C, et al. (2024) Sperm motility in mice with Oligo-astheno-teratozoospermia restored by in vivo injection and electroporation of naked mRNA. eLife. 2024;. Link: eLife
-
Yu, BY, et al. (2024) Dimethyl α-Ketoglutarate Promotes the Synthesis of Collagen and Inhibits Metalloproteinases in HaCaT Cells. Biomolecules & therapeutics. 2024; 32(2):240-248. PM ID: 38296652
-
McCorkle, JR, et al. (2024) Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. Cancers. 2024; 16(7). PM ID: 38610999
-
Dufner, A, et al. (2024) Ubiquitin-specific protease 8 controls B cell proteostasis and cell survival in multiple myeloma. bioRxiv. 2024;. Link: bioRxiv
-
Uddin, M, et al. (2024) Advancement of Radiolabeled Exosomes in Brain Disorders. Exosomes Based Drug Delivery Strategies for Brain Disorders. 2024;:325-392. Link: Exosomes Based Drug Delivery Strategies for Brain Disorders
-
Lin, RZ, et al. (2024) Mitochondrial transfer mediates endothelial cell engraftment through mitophagy. Nature. 2024; 629(8012):660-668. PM ID: 38693258
-
Abdoul-Azize, S, et al. (2024) Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling. Nature communications. 2024; 15(1):4557. PM ID: 38811530
-
Tanaka, N, et al. (2023) PRMT5-mediated methylation of STAT3 is required for lung cancer stem cell maintenance and tumour growth. Research Square. 2023;. Link: Research Square
-
Celik, A, et al. (2023) Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023; 161:114524. PM ID: 36948134
-
Brightman, SE, et al. (2023) Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors. Nature immunology. 2023; 24(8):1345-1357. PM ID: 37400675
-
Jeon, HM, et al. (2023) Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer cell. 2023;. PM ID: 37451272
-
Yamada-Hunter, S, et al. (2023) Engineered CD47 protects T cells for enhanced antitumor immunity. bioRxiv. 2023;. Link: bioRxiv
-
Pearson, S, et al. (2023) Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients. PloS one. 2023; 18(5):e0286412. PM ID: 37253035
-
Campelo, SN, et al. (2023) High-frequency irreversible electroporation improves survival and immune cell infiltration in rodents with malignant gliomas. Frontiers in oncology. 2023; 13:1171278. PM ID: 37213298
-
Sugita, M, et al. (2023) Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell death & disease. 2023; 14(5):305. PM ID: 37142568
- See More